Avalo Therapeutics (AVTX) Equity Ratio (2016 - 2025)
Historic Equity Ratio for Avalo Therapeutics (AVTX) over the last 12 years, with Q3 2025 value amounting to 0.73.
- Avalo Therapeutics' Equity Ratio rose 24185.06% to 0.73 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.73, marking a year-over-year increase of 24185.06%. This contributed to the annual value of 0.88 for FY2024, which is 15366.72% up from last year.
- Per Avalo Therapeutics' latest filing, its Equity Ratio stood at 0.73 for Q3 2025, which was up 24185.06% from 0.83 recorded in Q2 2025.
- In the past 5 years, Avalo Therapeutics' Equity Ratio registered a high of 0.89 during Q1 2025, and its lowest value of 0.91 during Q1 2024.
- Over the past 5 years, Avalo Therapeutics' median Equity Ratio value was 0.29 (recorded in 2021), while the average stood at 0.21.
- In the last 5 years, Avalo Therapeutics' Equity Ratio surged by 100475.43% in 2023 and then tumbled by 42591.46% in 2024.
- Quarter analysis of 5 years shows Avalo Therapeutics' Equity Ratio stood at 0.29 in 2021, then crashed by 213.68% to 0.33 in 2022, then soared by 206.36% to 0.35 in 2023, then soared by 153.67% to 0.88 in 2024, then decreased by 17.08% to 0.73 in 2025.
- Its Equity Ratio was 0.73 in Q3 2025, compared to 0.83 in Q2 2025 and 0.89 in Q1 2025.